All In Biotech

Drug Trial Radar · NCT07049562

Study on the Mass Balance of [14C]HRS-8427 for Injection in Healthy Chinese Subjects

Last checked: Nov 20, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

May 21, 2025

Primary completion

Jun 18, 2025

Study completion Jun 18, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the absorption, metabolism and excretion after a single intravenous infusion of \[14C\]HRS-8427 in healthy Chinese subjects

Conditions

  • Healthy Cninese Adult Male

Interventions

  • HRS-8427Drug

    \[14C\] HRS-8427 for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The total radioactive recovery rate and cumulative total radioactive recovery rate at each time interval in excreta (urine and feces)Time frame: 0~120hours
  2. The percentage (%AUC) of the potent drug and its metabolites in plasma, urine and feces to the administered doseTime frame: 0~120hours
  3. TmaxTime frame: 0~48hours
  4. CmaxTime frame: 0~48hours
  5. t1/2Time frame: 0~48hours
  6. MRTTime frame: 0~48hours
  7. AUCTime frame: 0~48hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.